SOHO 2021 | Treatment of advanced CTCL in 2021
Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, discusses the current treatment of advanced cutaneous T-cell lymphoma (CTCL) and explains how treatment is selected for different patient populations. Selecting treatments based on the anatomical compartment has shown to be more effective than previous strategies based on administrative route and response rate. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Transcript (edited for clarity)
The key points of my presentation are really to fine-tune how we’ve approached selection of treatment for patients with advanced cutaneous T-cell lymphomas. In the past, we’ve looked at things like what the route is, or what the response rate is, and we have a really long laundry list of treatments for this small patient population. However when I look at how I select treatments in clinic, and that is based on clinical trial data, I realized that in addition I’m looking at what compartments in the patient… I’m trying to target where the diseased cells are...
The key points of my presentation are really to fine-tune how we’ve approached selection of treatment for patients with advanced cutaneous T-cell lymphomas. In the past, we’ve looked at things like what the route is, or what the response rate is, and we have a really long laundry list of treatments for this small patient population. However when I look at how I select treatments in clinic, and that is based on clinical trial data, I realized that in addition I’m looking at what compartments in the patient… I’m trying to target where the diseased cells are. And I think going forward, that that might be a more useful and more precise way of selecting treatment for patients. And there is some basis in fact, scientifically, for approaching patients that way. That cells in a different environment may in fact be slightly different and respond differently to different drugs.
Read more...
